PT  - JOURNAL ARTICLE
AU  - Eva Koetsier
AU  - Sander M J van Kuijk
AU  - Paolo Maino
AU  - Jasmina Dukanac
AU  - Luca Scascighini
AU  - Alessandro Cianfoni
AU  - Pietro Scarone
AU  - Dominique E Kuhlen
AU  - Markus W Hollman
AU  - Jan-Willem Kallewaard
TI  - Efficacy of the Gelstix nucleus augmentation device for the treatment of chronic discogenic low back pain: protocol for a randomised, sham-controlled, double-blind, multicentre trial
AID  - 10.1136/bmjopen-2021-053772
DP  - 2022 Mar 01
TA  - BMJ Open
PG  - e053772
VI  - 12
IP  - 3
4099  - http://bmjopen.bmj.com/content/12/3/e053772.short
4100  - http://bmjopen.bmj.com/content/12/3/e053772.full
SO  - BMJ Open2022 Mar 01; 12
AB  - Introduction Discogenic pain is the cause of pain in 26%–40% of patients with for low back pain. Consensus about treatment of chronic discogenic low back pain is lacking and most treatment alternatives are supported by limited evidence. The percutaneous implantation of hydrogels into the nucleus pulposus represents a promising regenerative intradiscal therapy. The hydrogel ‘GelStix’ is composed primarily of hydrolyzed polyacrylonitrile and acts as a reservoir of hydration, producing increased pressure and improved pH balance, potentially leading to disc preservation. We hypothesise that treatment with GelStix will lead to greater reduction in pain intensity at 6 months post-treatment compared with patients receiving sham treatment.Methods and analysis This is a parallel group, randomised sham-controlled double-blind, multicentre trial to assess whether the GelStix device is superior to sham in reducing pain intensity in patients with chronic discogenic low back pain. The study will be conducted in two regional hospitals in Europe. Seventy-two participants will be randomised in a 1:1 ratio. The primary outcome will be the change in pain intensity between preoperative baseline and at 6 months postintervention. Secondary outcomes were disability, quality of life, the patient’s global impression of change scale, the use of pain medication and the disc degeneration process assessed by means of MRI. For change in pain intensity, disability, health-related quality of life and disc height, mean values will be compared between groups using linear regression analysis, adjusted for treatment centre.Ethics and dissemination Ethics approval was obtained from the Ethics Committee of the Canton Ticino, Switzerland (CE2982) and by the Medical Ethical Committee Arnhem-Nijmegen, the Netherlands (2016-2944). All patients that agree to participate will be asked to sign an informed consent form. Results will be disseminated through international publications in peer-reviewed journals, in addition to international conference presentations.Trial registration number NCT02763956.Protocol version 7.1, 18 November 2020.